From Life Extension
Testosterone normalization associated with lower risk of
heart attack, stroke and mortality from all causes over follow-up.
Tuesday, August 11,
2015. On August 5, 2015, an article published in European Heart Journal
reported that normalization of low testosterone levels through the use of
testosterone replacement therapy (TRT) was associated with a significant
decrease in the risk of myocardial infarction (MI, or heart attack), stroke and
premature mortality from all causes in a large group of male veterans.
The study included older men who received their medical care
at the Veterans Health Administration from December 1999 to May 2014. Subjects
were limited to men without a history of heart attack or ischemic stroke whose
initial total testosterone levels were below normal laboratory reference
ranges. These included 43,931 patients who had normal total testosterone levels
after receiving testosterone replacement therapy, 25,701 men who continued to
have subnormal testosterone after therapy, and 13,378 patients with low
testosterone who were untreated.
Over follow-up, the group with normalized testosterone
levels had 47% fewer deaths than men whose hormone levels failed to normalize
after testosterone replacement and 56% fewer deaths than those who did not
receive TRT. When myocardial infarction was evaluated, men whose testosterone
levels were normalized had an 18% lower risk than those whose levels failed to
normalize and a 24% lower risk than untreated men. Ischemic stroke risk in
normalized men was 30% lower than those who failed to attain normal
testosterone levels and 36% lower than those who did not receive the hormone.
As potential protective mechanisms, the authors cite testosterone's beneficial
effects on adipose tissue, insulin sensitivity and lipids, as well as its
anti-inflammatory and anticoagulant effects.
"In this study of men, without previous history MI or
stroke, with low testosterone levels, normalization of testosterone levels
using TRT is associated with lower mortality, fewer MIs, and strokes,"
corresponding author Rajat S. Barua, MD, concluded. "This is the first
study to demonstrate that significant benefit is observed only if the dose is
adequate to normalize the testosterone levels."
Please Note: Above statements are not written by Health Realizations nor the opinion of Health Realizations